-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Financial Comparison: Valneva (NASDAQ:VALN) & Miromatrix Medical (NASDAQ:MIRO)
Financial Comparison: Valneva (NASDAQ:VALN) & Miromatrix Medical (NASDAQ:MIRO)
Valneva (NASDAQ:VALN – Get Rating) and Miromatrix Medical (NASDAQ:MIRO – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.
Analyst Recommendations
This is a summary of current ratings and price targets for Valneva and Miromatrix Medical, as reported by MarketBeat.
Get Valneva alerts:Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Valneva | 1 | 2 | 1 | 0 | 2.00 |
Miromatrix Medical | 0 | 0 | 1 | 0 | 3.00 |
Valneva currently has a consensus price target of $25.00, indicating a potential upside of 95.31%. Miromatrix Medical has a consensus price target of $9.00, indicating a potential upside of 214.69%. Given Miromatrix Medical's stronger consensus rating and higher possible upside, analysts clearly believe Miromatrix Medical is more favorable than Valneva.
Volatility & Risk
Valneva has a beta of 2.99, meaning that its stock price is 199% more volatile than the S&P 500. Comparatively, Miromatrix Medical has a beta of -0.61, meaning that its stock price is 161% less volatile than the S&P 500.Valuation & Earnings
This table compares Valneva and Miromatrix Medical's gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Valneva | $411.85 million | 2.15 | -$86.87 million | N/A | N/A |
Miromatrix Medical | $30,000.00 | 1,992.37 | -$14.67 million | ($1.39) | -2.06 |
Miromatrix Medical has lower revenue, but higher earnings than Valneva.
Profitability
This table compares Valneva and Miromatrix Medical's net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Valneva | N/A | N/A | N/A |
Miromatrix Medical | -91,903.22% | -65.37% | -56.10% |
Insider & Institutional Ownership
16.4% of Valneva shares are held by institutional investors. Comparatively, 15.5% of Miromatrix Medical shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 4.9% of Miromatrix Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Valneva beats Miromatrix Medical on 7 of the 11 factors compared between the two stocks.
About Valneva
(Get Rating)
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
About Miromatrix Medical
(Get Rating)
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.
Valneva (NASDAQ:VALN – Get Rating) and Miromatrix Medical (NASDAQ:MIRO – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.
瓦爾內瓦(納斯達克:VALN-GET評級)和米羅矩陣醫療(納斯達克:MIRO-GET評級)都是小盤醫療公司,但哪隻股票更優越?我們將根據這兩家公司的盈利能力、分析師建議、機構所有權、風險、估值、收益和股息的強弱進行比較。
Analyst Recommendations
分析師建議
This is a summary of current ratings and price targets for Valneva and Miromatrix Medical, as reported by MarketBeat.
這是MarketBeat報道的Valneva和MiroMatrix Medical的當前評級和目標價的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Valneva | 1 | 2 | 1 | 0 | 2.00 |
Miromatrix Medical | 0 | 0 | 1 | 0 | 3.00 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
瓦爾尼瓦 | 1 | 2 | 1 | 0 | 2.00 |
微矩陣醫療 | 0 | 0 | 1 | 0 | 3.00 |
Valneva currently has a consensus price target of $25.00, indicating a potential upside of 95.31%. Miromatrix Medical has a consensus price target of $9.00, indicating a potential upside of 214.69%. Given Miromatrix Medical's stronger consensus rating and higher possible upside, analysts clearly believe Miromatrix Medical is more favorable than Valneva.
Valneva目前的共識目標價為25.00美元,表明潛在上行空間為95.31%。MiroMatrix Medical的共識目標價為9美元,表明潛在漲幅為214.69。考慮到米羅矩陣醫療更強的共識評級和更高的可能上行空間,分析師顯然認為米羅矩陣醫療比Valneva更有利。
Volatility & Risk
波動性與風險
Valuation & Earnings
估值與收益
This table compares Valneva and Miromatrix Medical's gross revenue, earnings per share (EPS) and valuation.
該表比較了Valneva和MiroMatrix Medical的毛收入、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Valneva | $411.85 million | 2.15 | -$86.87 million | N/A | N/A |
Miromatrix Medical | $30,000.00 | 1,992.37 | -$14.67 million | ($1.39) | -2.06 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
瓦爾尼瓦 | 4.1185億美元 | 2.15 | -8,687萬元 | 不適用 | 不適用 |
微矩陣醫療 | $30,000.00 | 1,992.37 | -1,467萬元 | ($1.39) | -2.06 |
Miromatrix Medical has lower revenue, but higher earnings than Valneva.
MiroMatrix Medical的收入低於Valneva,但收益高於Valneva。
Profitability
盈利能力
This table compares Valneva and Miromatrix Medical's net margins, return on equity and return on assets.
此表比較了Valneva和MiroMatrix Medical的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Valneva | N/A | N/A | N/A |
Miromatrix Medical | -91,903.22% | -65.37% | -56.10% |
淨利潤率 | 股本回報率 | 資產回報率 | |
瓦爾尼瓦 | 不適用 | 不適用 | 不適用 |
微矩陣醫療 | -91,903.22% | -65.37% | -56.10% |
Insider & Institutional Ownership
內部人與機構所有權
16.4% of Valneva shares are held by institutional investors. Comparatively, 15.5% of Miromatrix Medical shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 4.9% of Miromatrix Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valneva 16.4%的股份由機構投資者持有。相比之下,機構投資者持有MiroMatrix Medical 15.5%的股份。Valneva 14.9%的股份由公司內部人士持有。相比之下,MiroMatrix Medical 4.9%的股份由公司內部人士持有。強大的機構持股表明,捐贈基金、大型基金經理和對衝基金相信,從長期來看,一隻股票的表現將好於大盤。
Summary
摘要
Valneva beats Miromatrix Medical on 7 of the 11 factors compared between the two stocks.
Valneva在兩隻股票比較的11個因素中有7個擊敗了MiroMatrix Medical。
About Valneva
關於瓦爾尼瓦
(Get Rating)
(獲取評級)
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
Valneva SE是一家專業疫苗公司,專注於針對未得到滿足需求的傳染病的預防性疫苗的開發和商業化。該公司面向旅行者的商業疫苗包括IXIARO,一種以Vero細胞培養為基礎的滅活日本腦炎疫苗,用於主動免疫日本腦炎;杜考拉,一種口服疫苗,用於預防霍亂弧菌和/或產生產腸毒素大腸桿菌的不耐熱毒素引起的腹瀉;以及VLA2001,一種針對SARS-CoV-2的候選疫苗。該公司還開發了VLA15和VLA1553。VLA15是一種候選疫苗,已經完成了針對疏螺旋體的第二階段臨牀試驗;VLA1553是一種候選疫苗,正在進行鍼對基孔肯雅病毒的第三階段臨牀試驗。它的產品銷往美國、加拿大、德國、奧地利、北歐、英國、其他歐洲國家和國際市場。Valneva SE與輝瑞公司合作共同開發萊姆病疫苗並將其商業化,並與布坦坦研究所合作開發、製造和營銷單針基孔肯雅病疫苗。該公司成立於1998年,總部設在法國聖赫爾布賴恩。
About Miromatrix Medical
關於MiroMatrix醫療公司
(Get Rating)
(獲取評級)
Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota.
MiroMatrix醫療公司是一家生命科學公司,該公司開發了一種用於完全可移植器官的生物工程新技術。它的專利技術是一個平臺,使用脱細胞和再細胞的兩步法,旨在從豬的器官中移除豬細胞,並用未經修飾的人類細胞取代它們。該公司與梅奧診所、西奈山醫院和德克薩斯心臟研究所有合作關係。該公司前身為TayTech,Inc.,MiroMatrix Medical Inc.成立於2009年,總部位於明尼蘇達州伊甸園草原。
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.
接受Valneva Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Valneva和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧